

Submitter: Ana Holub  
On Behalf Of:  
Committee: House Committee On Behavioral Health and Health Care  
Measure, Appointment or Topic: HB2387

3/18/25

House Committee on Behavioral Health and Health Care  
900 Court Street NE  
Salem, Oregon 97301

RE: HB 2387 - Oregon Psilocybin Program Improvement Bill

Chair Nosse, Co-Chairs Javadi and Nelson, and Committee Members,

Thank you for the opportunity to share our support for HB 2387, the Psilocybin Program Improvement bill. My name is Ana Holub, and I am a licensed psilocybin facilitator located in Ashland, OR.

I am writing today to express my strong support for House Bill 2387, which makes critical improvements to Oregon's groundbreaking Psilocybin Services Program.

1. Currently, Oregon's healthcare providers—including nurses, doctors, and mental health professionals – cannot use their professional licenses when facilitating psilocybin services. HB 2387 creates licensure protections, which create legal protections for licensed healthcare providers to discuss psilocybin therapy with their patients. Without legal protections, healthcare providers fear losing their licenses, clients can not be fully informed, and adverse events are more likely to occur.

2. Many professionals are unclear if they can even discuss psilocybin therapy with patients, and many are unwilling to do so, due to the risk of losing their professional licenses. HB 2387 proposes dual licensure, which allows healthcare professionals who are also licensed psilocybin facilitators to utilize their healthcare expertise in preparation (pre-session) and integration (post-session) of psilocybin services. Administration will remain non-directive as defined by the OHA.

3. HB 2387 establishes new membership requirements for the Psilocybin

Advisory Board (OPAB). In order to advise the Oregon Health Authority in making recommendations for program changes and improvements, the Psilocybin Advisory Board needs to be composed of those with lived experience as licensed and professional psilocybin service providers. I support this change.

4. HB 2387 requires that psilocin be labeled on all psilocybin products, and requires facilitators to notify clients of potential increased potency of the product before their administration session, which provides for improved informed consent. I support this change as well.

Oregon has the opportunity to lead the nation in addressing mental health challenges with compassion and innovation. Please adopt the provisions in HB 2387, making Oregon's Psilocybin Therapy Program safer and more accessible for all who stand to benefit. Thank you.

Sincerely,  
Ana Holub